Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Michl U, Molfenter F, Graefen M, Tennstedt P, Ahyai S, Beyer B, Budäus L, Haese A, Heinzer H, Oh SJ, Salomon G, Schlomm T, Steuber T, Thederan I, Huland H, Tilki D.
Michl U, et al.
J Urol. 2015 Feb;193(2):479-83. doi: 10.1016/j.juro.2014.08.111. Epub 2014 Sep 6.
J Urol. 2015.
PMID: 25196656